insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

1/5 보강
NPJ breast cancer 📖 저널 OA 78.3% 2026
Retraction 확인
출처
PubMed DOI

Su A, Hong EC, Moxon N, Mellinger SL, Kelly T, Conlin AK, Topp ZZ, Newell P, Fredrich N, Massimino KP, Wu Y, Martel M, Redmond WL, Aliabadi-Wahle S, Sun Z, Imatani J, Stanton SE, Hanes DA, Simanonok M, Rosales W, Nielsen TJ, Page DB

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Su A, Hong EC, et al. (2026). Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.. NPJ breast cancer. https://doi.org/10.1038/s41523-026-00925-0
MLA Su A, et al.. "Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.." NPJ breast cancer, 2026.
PMID 41844644
DOI 10.1038/s41523-026-00925-0

Abstract

We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.

같은 제1저자의 인용 많은 논문 (1)